Sechi M - Search Results

1

Fisetin targets YB-1/RSK axis independent of its effect on ERK signaling: insights from in vitro and in vivo melanoma models.

Sechi M, Lall RK, Afolabi SO, Singh A, Joshi DC, Chiu SY, Mukhtar H, Syed DN. Sechi M, et al. Sci Rep. 2018 Oct 24;8(1):15726. doi: 10.1038/s41598-018-33879-w. Sci Rep. 2018. PMID: 30356079 Free PMC article.

2

Nanoformulation of natural products for prevention and therapy of prostate cancer.

Sanna V, Siddiqui IA, Sechi M, Mukhtar H. Sanna V, et al. Among authors: sechi m. Cancer Lett. 2013 Jun 28;334(1):142-51. doi: 10.1016/j.canlet.2012.11.037. Epub 2012 Nov 29. Cancer Lett. 2013. PMID: 23201598 Free PMC article. Review.

3

Resveratrol-loaded nanoparticles based on poly(epsilon-caprolactone) and poly(D,L-lactic-co-glycolic acid)-poly(ethylene glycol) blend for prostate cancer treatment.

Sanna V, Siddiqui IA, Sechi M, Mukhtar H. Sanna V, et al. Among authors: sechi m. Mol Pharm. 2013 Oct 7;10(10):3871-81. doi: 10.1021/mp400342f. Epub 2013 Sep 4. Mol Pharm. 2013. PMID: 23968375 Free PMC article.

4

Fisetin inhibits human melanoma cell growth through direct binding to p70S6K and mTOR: findings from 3-D melanoma skin equivalents and computational modeling.

Syed DN, Chamcheu JC, Khan MI, Sechi M, Lall RK, Adhami VM, Mukhtar H. Syed DN, et al. Among authors: sechi m. Biochem Pharmacol. 2014 Jun 1;89(3):349-60. doi: 10.1016/j.bcp.2014.03.007. Epub 2014 Mar 24. Biochem Pharmacol. 2014. PMID: 24675012 Free PMC article.

5

YB-1 expression promotes epithelial-to-mesenchymal transition in prostate cancer that is inhibited by a small molecule fisetin.

Khan MI, Adhami VM, Lall RK, Sechi M, Joshi DC, Haidar OM, Syed DN, Siddiqui IA, Chiu SY, Mukhtar H. Khan MI, et al. Among authors: sechi m. Oncotarget. 2014 May 15;5(9):2462-74. doi: 10.18632/oncotarget.1790. Oncotarget. 2014. PMID: 24770864 Free PMC article.

6

Resveratrol nanoformulation for cancer prevention and therapy.

Siddiqui IA, Sanna V, Ahmad N, Sechi M, Mukhtar H. Siddiqui IA, et al. Among authors: sechi m. Ann N Y Acad Sci. 2015 Aug;1348(1):20-31. doi: 10.1111/nyas.12811. Epub 2015 Jun 24. Ann N Y Acad Sci. 2015. PMID: 26109073 Review.

7

Dietary flavonoid fisetin binds to β-tubulin and disrupts microtubule dynamics in prostate cancer cells.

Mukhtar E, Adhami VM, Sechi M, Mukhtar H. Mukhtar E, et al. Among authors: sechi m. Cancer Lett. 2015 Oct 28;367(2):173-83. doi: 10.1016/j.canlet.2015.07.030. Epub 2015 Jul 30. Cancer Lett. 2015. PMID: 26235140 Free PMC article.

8

Nanoencapsulation of natural triterpenoid celastrol for prostate cancer treatment.

Sanna V, Chamcheu JC, Pala N, Mukhtar H, Sechi M, Siddiqui IA. Sanna V, et al. Among authors: sechi m. Int J Nanomedicine. 2015 Oct 30;10:6835-46. doi: 10.2147/IJN.S93752. eCollection 2015. Int J Nanomedicine. 2015. PMID: 26586945 Free PMC article.

9

Dual Inhibition of PI3K/Akt and mTOR by the Dietary Antioxidant, Delphinidin, Ameliorates Psoriatic Features In Vitro and in an Imiquimod-Induced Psoriasis-Like Disease in Mice.

Chamcheu JC, Adhami VM, Esnault S, Sechi M, Siddiqui IA, Satyshur KA, Syed DN, Dodwad SM, Chaves-Rodriquez MI, Longley BJ, Wood GS, Mukhtar H. Chamcheu JC, et al. Among authors: sechi m. Antioxid Redox Signal. 2017 Jan 10;26(2):49-69. doi: 10.1089/ars.2016.6769. Epub 2016 Oct 4. Antioxid Redox Signal. 2017. PMID: 27393705 Free PMC article.

10

Nanoencapsulation of dietary flavonoid fisetin: Formulation and in vitro antioxidant and α-glucosidase inhibition activities.

Sechi M, Syed DN, Pala N, Mariani A, Marceddu S, Brunetti A, Mukhtar H, Sanna V. Sechi M, et al. Mater Sci Eng C Mater Biol Appl. 2016 Nov 1;68:594-602. doi: 10.1016/j.msec.2016.06.042. Epub 2016 Jun 14. Mater Sci Eng C Mater Biol Appl. 2016. PMID: 27524059

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

89 results

Search Page